ASH 2022: Chemotherapy-free regimen ponatinib plus blinatumomab effective in patients with newly diagnosed Ph+ ALL
The chemotherapy-free regimen of ponatinib and blinatumomab achieved high response rates and reduced the need…
The chemotherapy-free regimen of ponatinib and blinatumomab achieved high response rates and reduced the need…
Cytotoxic chemotherapy followed by allogeneic bone marrow transplantation when feasible has been the standard of…